RT Journal Article
SR Electronic
T1 Determination of vancomycin exposure target and individualized dosing recommendations for ICU neonates: model informed precision dosing
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.03.30.20045971
DO 10.1101/2020.03.30.20045971
A1 Zhe Tang
A1 Jing Guan
A1 Jingjing Li
A1 Yanxia Yu
A1 Miao Qian
A1 Jiang Cao
A1 Weiwei Shuai
A1 Zheng Jiao
YR 2020
UL http://medrxiv.org/content/early/2020/07/10/2020.03.30.20045971.abstract
AB Background Few studies incorporating population pharmacokinetic/pharmacodynamic (Pop-PK/PD) modeling have been conducted to quantify the exposure target of vancomycin in neonates.Objectives (i) to derive vancomycin exposure target considering both vancomycin-induced acute kidney injury (AKI) and clinical efficacy in ICU neonates; (ii) to optimize dosing regimen of vancomycin in neonates based on PK/PD modeling and simulation.Methods This retrospective observational cohort study was registered at chictr.org.cn (ChiCTR1900027919). A Pop-PK model was developed to estimate individual PK parameters. Thresholds of vancomycin exposure in predicting AKI or efficacy were identified via classification and regression tree (CART) analysis. The association between exposure thresholds and clinical outcomes including AKI and efficacy was detected by logistic regression. Dosing recommendations were designed using Monte Carlo (MC) simulations based on the optimized exposure target.Results There were 182 neonates with 411 observations included in Pop-PK modeling. Covariate analysis showed that neonatal physiological maturation, renal function and conmitant use of vasoactive drugs (VAS) significantly affected vancomycin pharmacokinetics. AKI were screened for all patients. AUC0-24≥485 mg·h/L was an independent risk factor for AKI when adjusting for co-administration of VAS. Clinical efficacy of vancomycin was analyzed in 42 patients with blood culture-proved staphylococcal sepsis. AUC0-24/MIC≥234 was the only significant predictor for clinical effectiveness. MC simulations indicated that regimens in Neonatal Formulary 7 and Red Book (2018) were not suitable for all the neonates.Conclusions AUC0-24 of 240∼480 assuming MIC=1 mg/L is a recommended exposure target of vancomycin in neonates. The model informed dosing regimens are valuable in clinical practice.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis study has been registered at chictr.org.cn under identifier ChiCTR1900027919Funding StatementThis project was supported by Hospital Pharmacy Foundation of Nanjing Pharmaceutical Association (No. 2019YX004).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data of this study will be open to public through public access of medresman.org.cn within 6 months after publication. http://www.medresman.org.cn/pub/cn/proj/projectshshow.aspx?proj=1448